|
Treatment Options for Populations Vulnerable to Severe COVID-19
Treatment options for COVID-19 are evolving, and the Florida Department of Health wants to keep providers apprised of the currently available therapeutics for their patients. Up-to-date information on COVID-19 therapeutics can be found on the Department’s Treatment Locator.
Certain populations remain at a greater risk of progressing to severe COVID-19 and warrant more consideration for prophylaxis and/or treatment—specifically patients with certain pre-existing conditions and those 65 and older.
-
Paxlovid is an oral antiviral treatment that consists of nirmatrelvir tablets co-packaged and co-administered with ritonavir tablets. Paxlovid treatment must be initiated as soon as possible after COVID-19 diagnosis, within five days of symptom onset. Providers should be aware of the recent Health Advisory related to paxlovid.
-
Molnupiravir is an oral antiviral treatment that must be initiated as soon as possible after COVID-19 diagnosis, within five days of symptom onset. Molnupiravir should only be considered when other options are not appropriate or are unavailable.
-
Bebtelovimab, a monoclonal antibody treatment, must be administered as soon as possible after a positive SARS-CoV-2 viral test, within seven days of symptom onset.
-
Evusheld consists of co-packaged monoclonal antibodies (tixagevimab and cilgavimab) authorized for pre-exposure prophylaxis of COVID-19. Administering Evusheld as soon as possible may help protect patients who remain at risk despite the availability of COVID-19 vaccines.
-
Remdesivir, under the tradename VEKLURY, is now FDA approved as an outpatient early treatment option for patients diagnosed with mild-to-moderate COVID-19 and are at a high risk of severe disease. Providers should be aware that early, outpatient treatment with remdesivir consists of a 3-day course within seven days of symptom onset.
- If the current treatment options are not available or not appropriate, emerging treatments are available, including off-label use of fluvoxamine and inhaled budesonide.
- Providers should review the applicable Emergency Use Authorization and/or prescribing information before administering any options listed above.
About the Florida Department of Health
The Florida Department of Health, nationally accredited by the Public Health Accreditation Board, works to protect, promote and improve the health of all people in Florida through integrated state, county and community efforts.
Follow us on Facebook, Instagram and Twitter at @HealthyFla. For more information, please visit www.FloridaHealth.gov.
|
|
|
|
